Trial Profile
A Phase 1 Open-Label Study With Oral TR-701 FA to Assess Pharmacokinetics and Safety in Subjects With Moderate or Severe Hepatic Impairment
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Tedizolid (Primary)
- Indications Bacterial infections
- Focus Pharmacokinetics
- Sponsors Trius Therapeutics
- 11 Sep 2012 Interim results reported at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012)
- 07 Jun 2012 Actual end date (May 2012) added as reported by ClinicalTrials.gov.
- 07 Jun 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.